Stifel Maintains Buy on Summit Therapeutics, Raises Price Target to $40
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Bradley Canino has maintained a Buy rating on Summit Therapeutics and raised the price target from $25 to $40.
September 25, 2024 | 1:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel analyst Bradley Canino has maintained a Buy rating on Summit Therapeutics and increased the price target from $25 to $40, indicating a positive outlook.
The increase in the price target from $25 to $40 by Stifel suggests a strong positive outlook for Summit Therapeutics. This is likely to boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100